ArticleNeurochemical research2014
Gastrodin ameliorates memory deficits in 3,3'-iminodipropionitrile-induced rats: possible involvement of dopaminergic system.
Article in Neurochemical research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 31 citations in OpenAlex.
- Neuropharmacological effects ofFrontiers in neurology · 2025Review
- Gastrodin, a Promising Natural Small Molecule for the Treatment of Central Nervous System Disorders, and Its Recent Progress in Synthesis, Pharmacology and Pharmacokinetics.International journal of molecular sciences · 2024Review
- Synthesis, characterization and biological evaluation of aurones as potential neuroprotective agents.Future medicinal chemistry · 2024Article
- Gastrodin: a comprehensive pharmacological review.Naunyn-Schmiedeberg's archives of pharmacology · 2024Review
- Review on pharmacological effects of gastrodin.Archives of pharmacal research · 2023Review
- The GluN2B-Trp373 NMDA Receptor Variant is Associated with Autism-, Epilepsy-Related Phenotypes and Reduces NMDA Receptor Currents in Rats.Neurochemical research · 2022Article
- Treatment Combining Focused Ultrasound with Gastrodin Alleviates Memory Deficit and Neuropathology in an Alzheimer's Disease-Like Experimental Mouse Model.Neural plasticity · 2022Article
- Potential Targets and Action Mechanism of Gastrodin in the Treatment of Attention-Deficit/Hyperactivity Disorder: Bioinformatics and Network Pharmacology Analysis.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Effects of gastrodin on 5-HT and neurotrophic factor in the treatment of patients with post-stroke depression.Experimental and therapeutic medicine · 2018Article
- Decreased Number and Expression of nNOS-Positive Interneurons in Basolateral Amygdala in Two Mouse Models of Autism.Frontiers in cellular neuroscience · 2018Article
- A Review on Central Nervous System Effects of Gastrodin.Frontiers in pharmacology · 2018Review
- Ameliorative Effect of Ginsenoside Rg1 on Lipopolysaccharide-Induced Cognitive Impairment: Role of Cholinergic System.Neurochemical research · 2017Article
- Gastrodin reversed the traumatic stress-induced depressed-like symptoms in rats.Journal of natural medicines · 2016Article
- Gastrodin Attenuates Cognitive Deficits Induced by 3,3'-Iminodipropionitrile.Neurochemical research · 2016Article
- Time-Course Evaluation of Iminodipropionitrile-Induced Liver and Kidney Toxicities in Rats: A Biochemical, Molecular and Histopathological Study.Dose-response : a publication of International Hormesis SocietyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
3,3'-Iminodipropionitrile (IDPN), one of the nitrile derivatives, can induce neurotoxicity, and therefore cause motor dysfunction and cognitive deficits. Gastrodin is a main bioactive constituent of a Chinese herbal medicine (Gastrodia elata Blume) widely used for treating various neurological disorders and showed greatly improved mental function. This study was designed to determine whether administration of gastrodin attenuates IDPN-induced working memory deficits in Y-maze task, and to explore the underlying mechanisms. Results showed that exposure to IDPN (150 mg/kg/day, v.o.) significantly impaired working memory and that long-term gastrodin (200 mg/kg/day, v.o.) could effectively rescue these IDPN-induced memory impairments as indicated by increased spontaneous alternation in the Y-maze test. Additionally, gastrodin treatment prevented IDPN-induced reductions of dopamine (DA) and its metabolites, as well as elevation of dopamine turnover ratio (DOPAC + HVA)/DA. Gastrodin treatment also prevented alterations in dopamine D2 receptor and dopamine transporter protein levels in the rat hippocampus. Our results suggest that long-term gastrodin treatment may have potential therapeutic values for IDPN-induced cognitive impairments, which was mediated, in part, by normalizing the dopaminergic system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.